Long-Term Survival of a Patient with a Large Unresectable Hepatocellular Carcinoma: Case Report and Review of the Literature~!2010-04-28~!2010-05-29~!2010-07-23~!

Abstract

Amongst therapies for unresectable hepatocellular carcinomas, radiofrequency ablation (RFA) and hepatic artery chemoembolization have clinical application either for local tumor destruction or to control tumor progression and recurrence rate. Herein we present a patient with a large hepatocellular carcinoma, chronic hepatitis B and congenital absence of left hepatic lobe treated with hepatic artery chemoembolization, multiple RFA sessions and transarterial chemoembolizations resulted in long-term survival far beyond actual expected survival rate, while preserving quality of life.

Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection

“…The main risk factors include chronic infection by hepatitis B virus (HBV) and hepatitis C virus (HCV), alcohol abuse, aflatoxins, NAFLD, obesity, hemochromatosis and several genotoxic and nongenotoxic chemical carcinogens [282][283][284]. HCC treatment may involve surgical resection, liver transplantation, local ablative therapies, including radiofrequency ablation (RFA), percutaneous ethanol injection, and transcatheter arterial chemoembolization (TACE), chemotherapy, hormonotherapy and immunotherapy [285,286]. However, this is prohibitively expensive for many patients and benefits are limited [287].…”

Effectiveness of combined therapy radiofrequency ablation/transarterial chemoembolization versus transarterial chemoembolization/radiofrequency ablation on management of hepatocellular carcinoma

“…Regarding Milan criteria, there was significant downstaging after RFA/TACE (P < 0.05). First and second overall survival rates were 85% and 65% after TACE/RFA versus 100% and 74%, respectively, after RFA/TACE (P > By joining RFA and TACE for hepatic tumor treatment, induces large coagulative necrosis area without a possibility of revascularization [5], tumor progress or recurrence [6].…”

“…By joining RFA and TACE for hepatic tumor treatment, induces large coagulative necrosis area without a possibility of revascularization [5], tumor progress or recurrence [6].…”